Who Supplies Budesonide to India from COLOMBIA

To import finished pharmaceutical formulations containing Budesonide into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO) by submitting Form CT-20/40/41, which includes detailed product information, manufacturing processes, and quality control measures. The Drug Controller General of India (DCGI) must approve the product, ensuring it meets Indian standards. A No Objection Certificate (NOC) from the Ministry of Health and Family Welfare is also required. The registration process typically takes 6–12 months, depending on the completeness of the application and compliance with regulatory requirements. For Budesonide formulations under HS Code 30049099, the application must include stability data demonstrating a shelf life of at least 24 months under ICH Zone IV conditions. The product must comply with the Indian Pharmacopoeia standards, and the manufacturer must provide a Certificate of Pharmaceutical Product (CoPP) and a Certificate of Good Manufacturing Practice (GMP).

Imported Budesonide formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data under ICH Zone IV conditions must be provided to ensure product efficacy and safety. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the product. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of finished pharmaceutical formulations, including Budesonide. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and Colombia have facilitated smoother trade, but compliance with updated regulatory standards remains essential.

India imports finished Budesonide formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Budesonide formulations is limited, leading to a reliance on imports to fulfill market needs. The Indian market for Budesonide formulations is valued at approximately $50 million annually, with a steady growth rate of 5% per year.

The Basic Customs Duty (BCD) for Budesonide formulations under HS Code 30049099 is 10%. An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable, totaling 3%. The Countervailing Duty (CVD) is 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. The total landed duty is approximately 17.10%.

Colombia's pharmaceutical industry offers competitive advantages, including patented formulations and specialized dosage forms of Budesonide not available from other suppliers. The quality of Colombian products meets international standards, making them attractive to Indian importers. While other suppliers like China, Germany, and the US are present in the market, Colombia's unique offerings and quality position it favorably. Colombia holds a 5% share in India's Budesonide import market.

India imports Budesonide formulations from Colombia due to the availability of patented formulations and specialized dosage forms not produced domestically. Colombia's pharmaceutical industry offers high-quality products that meet international standards, making them attractive to Indian importers. Specific formulations, such as extended-release tablets, are sourced from Colombia to fulfill market demand.

Compared to other origins like China, the European Union, and the United States, Colombia offers competitive pricing and high-quality Budesonide formulations. While China may offer lower prices, concerns about quality and regulatory compliance exist. The European Union and the United States provide high-quality products but at higher prices. Colombia's unique advantage lies in its ability to offer specialized formulations at competitive prices while maintaining quality standards.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the past year. To mitigate risks, importers should consider dual-sourcing strategies and maintain buffer stocks.

1. 1Engage in dual-sourcing to reduce dependency on a single supplier.
2. 2Maintain adequate inventory levels to buffer against supply chain disruptions.
3. 3Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Ensure compliance with Minimum Order Quantities (MOQs) to optimize procurement costs.
5. 5Conduct thorough supplier qualification processes to assess reliability and quality standards.

1. 1Obtain a valid DGFT Importer Exporter Code (IEC).
2. 2Register the product with CDSCO by submitting Form CT-20/40/41.
3. 3Secure a Drug Import License from DGFT.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
5. 5Ensure the product complies with Indian Pharmacopoeia standards.
6. 6Provide stability data under ICH Zone IV conditions.
7. 7Ensure the manufacturer holds a valid Certificate of Pharmaceutical Product (CoPP) and Certificate of Good Manufacturing Practice (GMP).

1. Certificate of Analysis (CoA) for each batch.